For research use only. This reference describes BPC-157 strictly as a chemical compound used in cell-culture and animal research. Research-grade BPC-157 is not equivalent to, and is not a substitute for, any FDA-approved pharmaceutical product of a similar name. Nothing here is intended for human or animal consumption. We make no health, performance, or therapeutic claims of any kind. For the full context, see our research-use disclaimer.
BPC-157 — also called Body Protection Compound-157, and referenced in the literature as bepecin or by the development code PL-14736 — is a synthetic 15-amino-acid oligopeptide. The molecule is reported to be derived from a fragment of a larger protein found in human gastric juice, and that 15-residue stretch is widely cited as the activity-essential portion. What follows covers the peptide's primary structure, its unusually stable behavior in proteolytic environments, the in-vitro endpoints most often reported across the literature, the two signaling pathways characterized in endothelial cell models, and where the regulatory record sits today for researchers ordering material for laboratory work.
Primary structure and physicochemical identifiers
For a peptide that has accumulated this much in-vitro literature, BPC-157's structural identity is unusually well-defined. PubChem (CID 9941957) and the encyclopedia entry for the compound both list the primary sequence as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. You'll see the same sequence in supplier certificates of analysis and in the methods sections of the cell-culture papers cited later in this article.
Molecular formula and mass
The molecular formula is C62H98N16O22, with a calculated mass of approximately 1,419 Da. PubChem also provides a canonical SMILES string, an InChI, and an InChIKey — the identifiers chemical-supply databases use to disambiguate this pentadecapeptide from unrelated compounds whose acronyms also start with "BPC". When ordering reference material, the InChIKey is the cleanest single identifier to verify on a certificate of analysis.
Origin and naming
The 15-residue fragment is described in the foundational reviews as derived from a larger native protein in human gastric juice. The synthetic version prepared for laboratory work is chemically identical to that fragment as characterized — the same primary sequence, not a structural analog. One thing worth flagging: BPC-157 shares its name with an investigational drug code (PL-14736), so researchers should treat research-grade material sold for in-vitro use as not equivalent to, and not a substitute for, any FDA-approved pharmaceutical product of a similar name.
Stability profile in proteolytic environments
One practical reason BPC-157 has been adopted across so many in-vitro paradigms is its proteolytic stability. The comprehensive review by Sikiric and colleagues aggregates two decades of work and reports no measurable degradation of the 15-amino-acid fragment after 24 hours of incubation in human gastric juice under standard conditions. The same review describes the peptide as resistant to trypsin, chymotrypsin, and a panel of intracellular cathepsin proteases.
Structural rationale
The structural feature most often credited for that stability is the four proline residues distributed across the sequence. Proline imposes conformational constraints that interfere with the substrate binding many serine and cysteine proteases require, and the reviewers position this as the chemical basis for the molecule's behavior as a "stable gastric pentadecapeptide". For researchers planning timecourse assays — receptor expression studies, scratch-wound migration paradigms, Matrigel tube-formation experiments — that stability translates into predictable peptide concentrations across multi-day incubations without re-spiking the medium.
In-vitro endpoints reported across the literature
Published in-vitro work on BPC-157 clusters around two cell types: vascular endothelial cells and connective-tissue fibroblasts. The endpoints in each are well-defined and reproduced across multiple groups. That reproducibility is what makes the compound useful as a reference reagent in angiogenesis and proliferation assays.
Endothelial cell endpoints
In cultured human umbilical vein endothelial cells (HUVECs), incubation with BPC-157 has been reported to increase cell proliferation, accelerate scratch-wound migration, and produce more vascular tube structures in Matrigel assays compared with vehicle controls. The in-vitro arm of the alkali-burn study by Huang and colleagues documents all three of those readouts in HUVECs, with up-regulation of VEGF-A mRNA in some preparations. The VEGFR2 paper by Hsieh and colleagues reports the same proliferation and tube-formation endpoints, with concentration-responsive activity across the tested range.
Connective-tissue cell endpoints
Tendon fibroblasts tell a related story. In the study by Chang and colleagues, cultured cells respond to BPC-157 with concentration- and time-responsive up-regulation of growth hormone receptor (GHR) at both mRNA and protein levels, measured by RT real-time PCR and Western blot. The signal stayed detectable for at least 72 hours after a single peptide exposure — one in-vitro line of evidence consistent with the stability profile described above.
Common readouts across the field
Survey the literature and the same battery of endpoints appears again and again: cell-counting and BrdU proliferation assays, scratch-wound and Boyden-chamber migration assays, Matrigel tube formation, mRNA quantitation by qPCR, and protein quantitation by Western blot. These readouts characterize the compound's activity in defined chemical environments only. They don't establish human relevance.
Signaling pathways characterized in vitro
Two parallel signaling routes have been described in cell-culture models. Studies that interrogate one without the other tend to under-estimate the breadth of the response — which is why current methods sections increasingly include readouts from both.
VEGFR2-dependent route
The VEGFR2 paper reports that BPC-157 raises VEGFR2 mRNA and protein expression in human vascular endothelial cells in a concentration-responsive manner, while VEGF-A levels stay flat. The signal is propagated through internalization of VEGFR2 and downstream activation of the VEGFR2-Akt-eNOS axis. The authors interpret the finding as receptor-driven rather than ligand-driven: BPC-157 sensitizes endothelial cells to existing VEGF-A rather than producing more of it.
VEGF-independent Src / caveolin-1 / eNOS route
The Scientific Reports paper by Hsieh and colleagues uses ex-vivo aortic ring preparations and cultured endothelial cells to show that BPC-157 also stimulates endothelial nitric-oxide synthase (eNOS) phosphorylation through a Src kinase / caveolin-1 axis that operates independently of VEGFR2. Pretreatment with Src inhibitors abolishes the eNOS response. VEGFR2 blockade attenuates it but doesn't eliminate it. The authors propose a dual-pathway model — VEGFR2-dependent and Src-Cav-1-dependent — as one explanation for the breadth of pro-vascular activity reported across tissue types.
Implication for assay design
Researchers planning new in-vitro studies typically include both pathway readouts because either one alone misses part of the response. A practical methods section will pair VEGFR2 phosphorylation or downstream Akt-eNOS readouts with Src activity assays and caveolin-1 immunoprecipitation, reading them out in parallel rather than sequentially.
Preclinical safety pharmacology and regulatory status
The published preclinical safety record for BPC-157 includes the standard genotoxicity panels. The preclinical evaluation in Regulatory Toxicology and Pharmacology reports negative results in the Ames mutagenicity test, the in-vitro chromosome aberration assay, and the mouse-bone-marrow micronucleus assay under the conditions tested. Cytotoxicity in standard cell-culture panels was within typical no-effect ranges. The authors frame these results as supportive of the peptide's profile in research-use contexts — not as evidence for any human-use authorization.
Regulatory status
No regulatory authority — neither the FDA, the EMA, nor any other major agency — has authorized BPC-157 for human therapeutic use. The 2025 literature-and-patent review by Józwiak and colleagues aggregates roughly 30 years of preclinical work and is explicit about the gap between that record and any clinical-grade evidence. Commercial availability is restricted to the research-chemical channel. Researchers ordering material should treat BPC-157 as a cell-culture and animal-model reagent rather than a candidate therapeutic. For broader context on how Optides handles research-use peptides, see our research articles index.
Frequently Asked Questions
What is the amino-acid sequence of BPC-157?
BPC-157 is a 15-residue peptide with the primary sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its molecular formula is C62H98N16O22, with a molecular weight of approximately 1,419 Da. PubChem catalogues it as CID 9941957. Other names in the literature include Body Protection Compound-157, bepecin, and the development code PL-14736. For research use only — research-grade material is not equivalent to any FDA-approved pharmaceutical of a similar name.
Why is BPC-157 reported to be stable in human gastric juice?
Published incubation studies report no measurable degradation of BPC-157 after 24 hours in human gastric juice. The pentadecapeptide carries four proline residues, and review authors attribute its resistance to trypsin, chymotrypsin, and various intracellular cathepsin proteases to the conformational rigidity those residues impose. That stability profile is one of the structural features that distinguishes BPC-157 from many other small bioactive peptides used in cell-culture work.
Through what signaling pathways does BPC-157 act in cell-culture studies?
Two cell-culture pathways have been characterized. The first is VEGFR2-dependent: BPC-157 increases VEGFR2 mRNA and protein expression in human vascular endothelial cells, drives receptor internalization, and activates the VEGFR2-Akt-eNOS axis without raising VEGF-A levels. The second is VEGF-independent and runs through Src kinase and caveolin-1 to activate endothelial nitric-oxide synthase. The two pathways are reported to operate in parallel in endothelial cell models. For research use only.
Has BPC-157 been approved for human use?
No regulatory authority has approved BPC-157 for human therapeutic use. The published evidence base is preclinical — cell-culture and animal models — and a 2025 literature-and-patent review explicitly notes the gap between that preclinical record and any clinical-grade evidence. Research-grade material sold for in-vitro work is not equivalent to and is not a substitute for any FDA-approved pharmaceutical product.
Conclusion
BPC-157 is a structurally well-defined 15-residue peptide. Its chemical identity (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; formula C62H98N16O22; PubChem CID 9941957) is unambiguous. Its proteolytic stability — anchored in four proline residues — supports the multi-day timecourses common in cell-culture work. The in-vitro literature reports reproducible endpoints across endothelial and connective-tissue cell types, and the two parallel signaling routes (VEGFR2-Akt-eNOS and Src-Cav-1-eNOS) characterized in endothelial models capture much of the response. The preclinical-to-clinical gap is the limiting factor; researchers should treat BPC-157 as a cell-culture and animal-model reagent rather than a candidate therapeutic. For research use only.
For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.
Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.